Attached files
file | filename |
---|---|
8-K - FORM 8-K - BAXANO SURGICAL, INC. | g22269e8vk.htm |
EX-10.1 - EX-10.1 - BAXANO SURGICAL, INC. | g22269exv10w1.htm |
EX-99.3 - EX-99.3 - BAXANO SURGICAL, INC. | g22269exv99w3.htm |
EX-99.2 - EX-99.2 - BAXANO SURGICAL, INC. | g22269exv99w2.htm |
Exhibit 99.1
TranS1 Inc. Reports Operating Results for the Fourth Quarter of 2009
Highlights:
Fourth quarter revenues were $6.3 million
674 TranS1 procedures performed globally in the quarter
Gross margin was 79.9% for the quarter
GAAP loss per share was $0.28 for the quarter
Non-GAAP loss per share was $0.25 for the quarter
WILMINGTON, NC (GLOBE NEWSWIRE)February 23, 2010TranS1 Inc. (NASDAQ:TSON), a medical device
company focused on designing, developing and marketing products that implement its proprietary
minimally invasive surgical approach to treat degenerative disc disease and instability affecting
the lower lumbar region of the spine, today announced its financial results for the fourth quarter
ended December 31 2009.
Revenues were $6.3 million in the fourth quarter of 2009, representing a 15% decrease over revenues
of $7.4 million in the fourth quarter of 2008. Gross margin was 79.9% in the fourth quarter of
2009 as compared to 84.6% in the fourth quarter of 2008.
Operating expenses were $10.7 million in the fourth quarter of 2009 compared to $11.1 million in
the fourth quarter of 2008. The decrease in operating expenses is primarily attributable to a
decrease in sales and marketing costs as a result of the decreased commissions due to lower sales,
partially offset by increased spending for research and development.
Net loss was $5.7 million and $4.5 million for the quarters ended December 31 2009 and 2008,
respectively. GAAP net loss per common share was $0.28 in the fourth quarter of 2009 compared to
a net loss per share of $0.22 in the fourth quarter of 2008.
For the quarters ended December 31 2009 and 2008, on a non-GAAP basis adjusting for non-cash stock
compensation expense, net loss per common share was $0.25 and $0.20, respectively.
Cash, cash-equivalents and investments were $55.3 million as of December 31 2009.
Our results this quarter, and for much of 2009, were impacted by concerns in the marketplace
surrounding reimbursement for our AxiaLIF procedure. We are using the experience we gained in 2009
to better educate and support our current and prospective surgeon users as they navigate the
current reimbursement landscape, said Rick Randall,
CEO of TranS1. We are approaching 2010 with a leaner, more experienced sales force armed with a
broader product offering to expand our clinical indications within the lumbar spine.
Conference Call
TranS1 will host a conference call today at 4:30 pm ET to discuss its fourth quarter financial
results. To listen to the conference call on your telephone, please dial (877) 881-2183 for
domestic callers and (970) 315-0453 for international callers approximately ten minutes prior to
the start time. The call will be concurrently webcast. To access the live audio broadcast or the
archived recording, use the following link at http://ir.trans1.com/events.cfm.
Non-GAAP Measures
Management uses certain non-GAAP financial measures such as non-GAAP net loss and net loss per
share, which exclude stock based compensation. This non-GAAP presentation is given in part to
enhance the understanding of the companys historical financial performance and comparability
between periods. The company believes that the non-GAAP presentation to exclude stock-based
compensation is relevant and useful information that will be widely used by investors and analysts.
Accordingly, the company is disclosing this information to permit additional analysis of the
companys performance. These non-GAAP measures are not in accordance with, or an alternative for,
GAAP, and may be different from non-GAAP measures used by other companies. Investors should
consider these non-GAAP measures in addition to, and not as a substitute for, financial performance
measures in accordance with GAAP. A reconciliation of the GAAP financial measures to the
comparable non-GAAP financial measure is included below.
About TranS1 Inc.
TranS1 is a medical device company focused on designing, developing and marketing products that
implement its proprietary minimally invasive surgical approach to treat degenerative disc disease
and instability affecting the lower lumbar region of the spine. TranS1 currently markets the
AxiaLIF family of products for single and multilevel lumbar fusion and the Vectre and Avatar
posterior fixation systems for lumbar fixation supplemental to AxiaLIF fusion. TranS1 was founded
in May 2000 and is headquartered in Wilmington, North Carolina. For more information, visit
www.trans1.com.
Forward-Looking Statements
This press release includes forward-looking statements, the accuracy of which is necessarily
subject to risks and uncertainties. These risks and uncertainties include, among other things,
risks associated with the adoption of a new technology by spine surgeons, product development
efforts, regulatory requirements, maintenance and prosecution of adequate intellectual property
protection and other economic and competitive factors. These forward looking statements are based
on the companys expectations as of the date of this press release and the company undertakes no
obligation
to update information provided in this press release. For a discussion of risks and uncertainties
associated with TranS1s business, please review the companys filings with the Securities and
Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2008.
CONTACT:
Investors:
TranS1 Inc.
Michael Luetkemeyer, 910-332-1700
Chief Financial Officer
Investors:
TranS1 Inc.
Michael Luetkemeyer, 910-332-1700
Chief Financial Officer
or
Westwicke Partners
Mark Klausner, 443-213-0501
mark.klausner@westwicke.com
Source: TranS1 Inc.
Mark Klausner, 443-213-0501
mark.klausner@westwicke.com
Source: TranS1 Inc.
TranS1 Inc.
Statements of Operations
(in thousands, except per share amounts)
(Unaudited)
Statements of Operations
(in thousands, except per share amounts)
(Unaudited)
Three Months Ended Dec. 31, | Twelve Months Ended Dec. 31, | |||||||||||||||
2009 | 2008 | 2009 | 2008 | |||||||||||||
Revenue |
$ | 6,279 | $ | 7,354 | $ | 29,807 | $ | 25,304 | ||||||||
Cost of revenue |
1,264 | 1,129 | 5,687 | 4,315 | ||||||||||||
Gross profit |
5,015 | 6,225 | 24,120 | 20,989 | ||||||||||||
Operating expenses: |
||||||||||||||||
Research and development |
1,392 | 839 | 6,439 | 4,081 | ||||||||||||
Sales and marketing |
7,878 | 8,696 | 34,098 | 29,375 | ||||||||||||
General and administrative |
1,471 | 1,554 | 7,184 | 7,116 | ||||||||||||
Total operating expenses |
10,741 | 11,089 | 47,721 | 40,572 | ||||||||||||
Operating loss |
(5,726 | ) | (4,864 | ) | (23,601 | ) | (19,583 | ) | ||||||||
Interest income |
23 | 331 | 405 | 2,548 | ||||||||||||
Net loss |
$ | (5,703 | ) | $ | (4,533 | ) | $ | (23,196 | ) | $ | (17,035 | ) | ||||
Net loss per
common share basic and diluted |
$ | (0.28 | ) | $ | (0.22 | ) | $ | (1.13 | ) | $ | (0.84 | ) | ||||
Weighted average common
shares outstanding basic and diluted |
20,641 | 20,534 | 20,604 | 20,289 | ||||||||||||
Stock-based compensation
is included in operating
expenses in the following
categories: |
||||||||||||||||
Cost of revenue |
$ | 19 | $ | 21 | $ | 74 | $ | 66 | ||||||||
Research and development |
45 | 18 | 186 | 412 | ||||||||||||
Sales and marketing |
338 | 154 | 1,481 | 1,474 | ||||||||||||
General and administrative |
198 | 189 | 1,058 | 1,027 | ||||||||||||
$ | 600 | $ | 382 | $ | 2,799 | $ | 2,979 | |||||||||
Reconciliation of Quarterly Results
(in thousands, except per share amounts)
(Unaudited)
(in thousands, except per share amounts)
(Unaudited)
2009 | 2008 | |||||||
GAAP net loss |
$ | (5,703 | ) | $ | (4,533 | ) | ||
Stock based compensation |
600 | 382 | ||||||
Non-GAAP net loss |
$ | (5,103 | ) | $ | (4,151 | ) | ||
Shares used in computing GAAP and non-GAAP loss
per share |
20,641 | 20,534 | ||||||
Non-GAAP loss per share |
$ | (0.25 | ) | $ | (0.20 | ) | ||
Reconciliation of Year-To-Date Results
(in thousands, except per share amounts)
(Unaudited)
(in thousands, except per share amounts)
(Unaudited)
2009 | 2008 | |||||||
GAAP net loss |
$ | (23,196 | ) | $ | (17,035 | ) | ||
Stock based compensation |
2,799 | 2,979 | ||||||
Non-GAAP net loss |
$ | (20,397 | ) | $ | (14,056 | ) | ||
Shares used in computing GAAP and non-GAAP loss
per share |
20,604 | 20,289 | ||||||
Non-GAAP loss per share |
$ | (0.99 | ) | $ | (0.69 | ) | ||
TranS1 Inc.
Balance Sheets
(in thousands)
(Unaudited)
Balance Sheets
(in thousands)
(Unaudited)
December 31, | December 31, | |||||||
2009 | 2008 | |||||||
Assets |
||||||||
Current assets: |
||||||||
Cash and cash equivalents |
$ | 29,298 | $ | 42,051 | ||||
Short-term investments |
25,953 | 35,215 | ||||||
Accounts receivable, net |
3,926 | 4,812 | ||||||
Inventory |
7,325 | 6,369 | ||||||
Prepaid expenses and other assets |
676 | 632 | ||||||
Total current assets |
67,178 | 89,079 | ||||||
Property and equipment, net |
1,813 | 1,412 | ||||||
Total assets |
$ | 68,991 | $ | 90,491 | ||||
Liabilities and Stockholders Equity |
||||||||
Current liabilities: |
||||||||
Accounts payable |
$ | 2,442 | $ | 2,896 | ||||
Accrued expenses |
1,269 | 2,009 | ||||||
Total current liabilities |
3,711 | 4,905 | ||||||
Stockholders equity |
||||||||
Common stock |
2 | 2 | ||||||
Additional paid-in capital |
136,402 | 133,507 | ||||||
Accumulated other comprehensive income |
(5 | ) | | |||||
Accumulated deficit |
(71,119 | ) | (47,923 | ) | ||||
Total stockholders equity |
65,280 | 85,586 | ||||||
Total liabilities and
stockholders equity |
$ | 68,991 | $ | 90,491 | ||||
TranS1 Inc.
Statements of Cash Flows
(in thousands)
(Unaudited)
Statements of Cash Flows
(in thousands)
(Unaudited)
Twelve Months Ended Dec. 31, | ||||||||
2009 | 2008 | |||||||
Cash flows from operating activities: |
||||||||
Net loss |
$ | (23,196 | ) | $ | (17,035 | ) | ||
Adjustments to reconcile net loss to net
cash used in operating activities |
||||||||
Depreciation |
909 | 804 | ||||||
Stock-based compensation |
2,799 | 2,979 | ||||||
Allowance for excess and obsolete
inventory |
505 | 400 | ||||||
Provision for bad debts |
80 | 101 | ||||||
Changes in operating assets and
liabilities: |
||||||||
(Increase) decrease
in accounts receivable |
806 | (1,688 | ) | |||||
(Increase) decrease
in inventory |
(1,461 | ) | (2,744 | ) | ||||
(Increase) decrease
in prepaid expenses |
(44 | ) | (35 | ) | ||||
Increase (decrease)
in accounts payable |
(454 | ) | 1,265 | |||||
Increase (decrease)
in accrued expenses |
(740 | ) | 223 | |||||
Net cash used in operating activities |
(20,796 | ) | (15,730 | ) | ||||
Cash flows from investing activities: |
||||||||
Purchase of property and equipment |
(1,310 | ) | (1,128 | ) | ||||
Purchases of investments |
(50,872 | ) | (55,761 | ) | ||||
Sales and maturities of short-term investments |
60,134 | 49,791 | ||||||
Net cash provided by (used in) investing activities |
7,952 | (7,098 | ) | |||||
Cash flows from financing activities: |
||||||||
Proceeds from issuance of common stock |
91 | 203 | ||||||
Net cash provided by (used in) financing activities |
91 | 203 | ||||||
Net decrease in cash and cash equivalents |
(12,753 | ) | (22,625 | ) | ||||
Cash and cash equivalents, beginning of period |
42,051 | 64,676 | ||||||
Cash and cash equivalents, end of period |
$ | 29,298 | $ | 42,051 | ||||